as seen in Targeting Trends Newsletter, Jan-Feb-Mar 2005
Toxicology studies with the potential chronic pain therapeutic, SP-SAP (Substance P-Saporin) are continuing successfully. The second study will be initiated in a few months and ATS is diligently pursuing a pharmaceutical partner that can quickly bring the drug to clinical trials in humans.
With the recent news of the undesirable side effects of such pain drugs as Vioxx and Celebrex, the need for a safe, effective chronic pain therapeutic becomes more urgent every day. ATS acknowledges its expertise as a research supply company does not provide the necessary elements for successful drug development. For this reason, an immediate alliance is sought with a partner experienced in bringing a drug to approval and dedicated to the needs of chronic pain patients.